Back

Structure of hepatitis B/D antiviral drug Bulevirtide bound to its receptor protein NTCP

Liu, H.; Zakrzewicz, D.; Nosol, K.; Irobalieva, R. N.; Mukherjee, S.; Bang-Soerensen, R.; Goldmann, N.; Kunz, S.; Rossi, L.; Kossiakoff, A. A.; Urban, S.; Glebe, D.; Geyer, J.; Locher, K. P.

2024-01-22 biochemistry
10.1101/2024.01.22.576510 bioRxiv
Show abstract

Cellular entry of the hepatitis B and D viruses (HBV/HDV) require binding of the viral surface polypeptide preS1 to the hepatobiliary transporter NTCP. This interaction can be blocked by bulevirtide (BLV, formerly Myrcludex B), a preS1 derivative and approved drug for treating HDV infection. To elucidate the basis of this inhibitory function, we determined a cryo-EM structure of BLV-bound human NTCP. BLV forms two domains, a plug lodged in the bile salt transport tunnel of NTCP and a string that covers the receptors extracellular surface. The N-terminally attached myristoyl group of BLV interacts with the lipid-exposed surface of NTCP. Our structure reveals how BLV inhibits bile salt transport, rationalizes NTCP mutations that decrease the risk of HBV/HDV infection, and provides a basis for understanding the host specificity of HBV/HDV. Our results provide opportunities for structure-guided development of inhibitors that target HBV/HDV docking to NTCP.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.